

CERTIFICATE OF ANALYSIS No.: 2024-15071

CLIENT

Pharmahemp d.o.o., Cesta v Gorice 8
1000 Ljubljana, Slovenija

SAMPLE *

CBD EXTRACT PHUD



Sample condition: SUITABLE

Sample ID: 2435018

Sample type: Resinous material

Batch No.: * EPD67024243A

Work order: 2024-111302

Analysis ID: 2024_288

Method ID: PHL_RPC_16C

Method SOP: MET-LAB-001-08

Sample received: 30/08/2024

Start of analysis: 30/08/2024

End of analysis: 02/09/2024

Analyst: Valentina Malin

* Information provided by the client.

| CANNABINOID PROFILE | | Concentration [% w/w] | Expanded uncertainty [% w/w] | Graphic presentation of relative cannabinoid concentration |
|---------------------------|-----------------------------------|--------------------------|------------------------------------|---|
| CBDV | - Cannabidivarin | 0.545 | 0.065 | <div></div> |
| CBDA | - Cannabidiolic acid | < LOQ | n/a | <div></div> |
| CBGA | - Cannabigerolic acid | < LOQ | n/a | <div></div> |
| CBG | - Cannabigerol | 1.73 | 0.12 | <div></div> |
| CBD | - Cannabidiol | 68.2 | 3.4 | <div></div> |
| THCV | - Tetrahydrocannabivarin | < LOQ | n/a | <div></div> |
| CBN | - Cannabinol | 2.53 | 0.13 | <div></div> |
| Δ⁹-THC | - Δ-9-Tetrahydrocannabinol | < LOQ | n/a | <div></div> |
| Δ⁸-THC | - Δ-8-Tetrahydrocannabinol | < LOQ | n/a | <div></div> |
| CBL | - Cannabicyclol | 0.354 | 0.060 | <div></div> |
| CBC | - Cannabichromene | 2.88 | 0.14 | <div></div> |
| Δ⁹-THCA | - Δ-9-Tetrahydrocannabinolic acid | < LOQ | n/a | <div></div> |
| CBV | - Cannabivarin | < LOQ | n/a | <div></div> |
| CBCA | - Cannabichromenic acid | < LOQ | n/a | <div></div> |
| CBT | - Cannabicitran | 5.15 | 0.26 | <div></div> |
| CBE | - Cannabielsoin | 2.94 # | 0.29 | <div></div> |

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.

The results given herein apply only to the sample as received and tested. **Expanded Uncertainty** was calculated using coverage factor $k = 2$, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

02/09/2024

Approved by:

mag. Janja Ahej

Analytical Laboratory Manager

Authorized by:

dr. Boštjan Jančar

Chief Technology Officer

End of Certificate